Telmisartan and cardioprotection by Akhrass, Philippe R & McFarlane, Samy I
© 2011 Akhrass and McFarlane, publisher and licensee Dove Medical Press Ltd.   This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Vascular Health and Risk Management 2011:7 677–683
Vascular Health and Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
677
ReView
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/VHRM.S9447
Telmisartan and cardioprotection
Philippe R Akhrass
Samy i McFarlane
State University of New York, 
Downstate Medical Center,  
Brooklyn, NY, USA
Correspondence: Samy i McFarlane 
State University of New York, Downstate  
Medical Center, Kings County Hospital  
Center, 450 Clarkson Avenue,  
Box 50, Brooklyn, NY 11203, USA 
Tel +1 718 270 3711 
Fax +1 718 270 6358 
email samy.mcfarlane@downstate.edu
Abstract: Cardiovascular risk reduction has been the target of several large clinical trials in 
the last decade. As the activation of the renin-angiotensin-aldosterone system (RAAS) plays a 
central role in the pathogenesis of atherosclerosis and cardiovascular disease, RAAS blockade has 
been suggested to be among the most efficient cardioprotective interventions, as revealed with 
the angiotensin converting enzyme (ACE) inhibitors trials. The angiotensin receptor blockers’ 
(ARBs) efficacy in lowering blood pressure has been very well established. Telmisartan is however 
the first ARB to show a promising role in reducing cardiovascular risk in high-risk patients. This 
article will highlight the role of telmisartan in cardioprotection, underlying specifically the results 
of two major randomized controlled trials: ONTARGET (ONgoing Telmisartan Alone and in 
combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized 
AssessmeNt Study in aCE-iNtolerant subjects with cardiovascular Disease).
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Introduction
Although death rates from cardiovascular disease have significantly declined over the 
last 10 years, the burden of the disease remains very high. In 2006, cardiovascular 
disease was responsible for 34.3% (831,272) of all deaths in the US. The estimated 
direct and indirect cost of cardiovascular disease for 2010 is US$503.2 billion.1 A great 
deal of effort has been directed toward treating cardiovascular and controlling its 
traditional risk factors.
The chronic activation of the renin-angiotensin-aldosterone system (RAAS) plays 
a central role in the pathogenesis of atherosclerosis, hypertension, left ventricular 
hypertrophy (LVH), myocardial infarction, and heart failure.2 The inhibition of the 
RAAS can be achieved by inhibiting the angiotensin-converting enzyme (ACE) or 
by directly blocking the angiotensin receptors. The use of ACE inhibitors is known 
to reduce mortality and cardiovascular risk in high-risk patients.3 On the other hand, 
the use of angiotensin receptor blockers (ARBs) is well established for the treatment 
of hypertension and in patients with heart failure or following myocardial infarction. 
Until recently, their role in cardioprotection remained unclear.
This review article highlights the results of the clinical trials examining the 
efficacy of the ARB telmisartan across the cardiovascular spectrum (Table 1). 
The   cardioprotective role of telmisartan is further discussed in the review of the 
  ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial) and TRANSCEND (Telmisartan Randomized AssessmeNt Study in 
aCE-iNtolerant subjects with cardiovascular Disease) studies.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Telmisartan and blood pressure  
(BP) control
Hypertension is a major risk factor for cardiovascular   disease. 
The ARBs are broadly effective in lowering BP with   relatively 
few side effects, notably the absence of cough and angioedema, 
which represents their major advantage over ACE inhibitors. 
Telmisartan is an ARB that was approved by the Food and 
Drug Administration (FDA) for the   treatment of hypertension 
in November 1998, and is proven to provide efficient and lasting 
BP control when compared to other agents. In one meta-analysis 
of 28 randomized controlled trials involving 5157 patients, 
telmisartan had a superior BP control over different ACE 
inhibitors (enalapril, ramipril, and perindopril), fewer drug-
related adverse events, and better tolerability in hypertensive 
patients.4 In another meta-analysis of eleven studies involving 
1832 patients, telmisartan resulted in a significant reduction in 
diastolic BP (weighted mean difference 1.52 mmHg; 95% con-
fidence interval [CI]: 0.85–2.19) and systolic BP (2.77 mmHg; 
95% CI: 1.90–3.63) when compared with losartan, as well as a 
significant reduction in 24-hour mean ambulatory BP.5
Furthermore, evidence suggests that cardiovascular risk 
may be subject to circadian variation, with peak morning 
incidence of myocardial infarction and stroke correlat-
ing with the early morning BP surge. Antihypertensive 
agents differ in their ability to control 24-hour BP. Ideally 
  antihypertensive therapy should maintain control of BP 
throughout the 24-hour dosing cycle and especially in the last 
6 hours of the cycle. In two prospective trials, PRISMA I and 
II (Prospective, Randomized Investigation of the Safety and 
efficacy of Micardis vs ramipril using Ambulatory BP moni-
toring) patients with essential hypertension were random-
ized to receive   telmisartan 80 mg/day (n = 802) or ramipril 
5 mg/day or 10 mg/day (n = 811) for 14 weeks.6 The primary 
endpoint was the change from baseline in mean ambulatory 
systolic BP and diastolic BP during the final 6 hours of the 
24-hour dosing cycle. After 14 weeks, telmisartan was more 
effective than ramipril in controlling BP throughout the 
24-hour period and during the early morning (mean systolic/
diastolic −4.1/−3.0 mmHg, P , 0.0001). These results may 
be attributable to the long effect duration of telmisartan, which 
is sustained throughout the 24-hour dosing period.6
Telmisartan, urinary protein  
excretion, and cardiovascular risk
The importance of urinary protein excretion as a cardio-
vascular risk factor has been established by a number of 
large studies. The HOPE (Heart Outcomes Prevention Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Evaluation) study, which included 9043 high-risk patients, 
showed a correlation between the degree of albuminuria and 
  cardiovascular risk, both in individuals with and without 
  diabetes. After adjustment for other risk factors, the relative 
risk (RR) of major cardiovascular events (cardiovascular 
death, myocardial infarction, or stroke) associated with 
microalbuminuria was 1.83 (95% CI: 1.64–2.05).7 ACE 
inhibitors are well known to reduce microalbuminuria and 
improve renal function. In the DETAIL (Diabetics Exposed 
to Telmisartan and Enalapril) trial, telmisartan was not 
inferior to the ACE inhibitor enalapril in preventing the 
progression of renal dysfunction, measured as the decline 
in the glomerular filtration rate in patients with diabetes.8 
Furthermore, in the INNOVATION (Incipient to Overt: 
Angiotensin II Blocker, Telmisartan, Investigation on Type 2 
Diabetic Nephropathy) study, 527 diabetic hypertensive and 
normotensive Japanese patients with microalbuminuria were 
randomized to telmisartan 40 mg, telmisartan 80 mg, or 
placebo.9 The transition to overt diabetic nephropathy was 
dose dependent and significantly lower in the telmisartan 
80 mg and telmisartan 40 mg groups compared with placebo 
(16.7% and 22.6% vs 49.9%, respectively; P , 0.0001) 
over a 30-month follow up period. Telmisartan also reduced 
transition to overt nephropathy in normotensive patients, 
suggesting a BP independent effect.9 In the VIVALDI 
(inVestIgate the efficacy of telmisartan versus VALsartan in 
hypertensive type 2 DIabetic) trial, telmisartan 80 mg/day and 
valsartan 160 mg/day produced similar reductions in 24-hour 
urinary protein excretion rates by 33% after 12 months of 
treatment in diabetic patients with hypertension and overt 
nephropathy.10 It is thought that their renoprotective benefit 
in VIVALDI, was solely due to the antihypertensive effect. 
However, in the AMADEO (A comparison of telMisartan 
versus losArtan in hypertensive type 2 DiabEtic patients 
with Overt nephropathy) trial, telmisartan 80 mg/day was 
superior to losartan 100 mg/day in terms of renoprotective 
properties. Telmisartan showed a greater reduction in the 
urinary albumin to creatinine ratio than the losartan (29.8% 
and 21.4%, respectively; P , 0.031), despite similar BP 
reduction.11
Telmisartan and prevention  
of cardiovascular disease  
in high-risk patients
Multiple randomized controlled trials demonstrated   reduction 
of mortality and hospital admissions in patients with heart 
failure when treated with an ARB.12 When compared to 
atenolol, ARBs decreased vascular events in patients with 
hypertension and LVH.13 In addition, ARBs were comparable 
to ACE inhibitors in patients with acute myocardial infarction 
and heart failure in terms of all-cause mortality.14
The ONTARGET trial is a landmark large trial that estab-
lished the role of ARBs in reducing cardiovascular events 
in high-risk patients.15 ONTARGET studied patients with 
coronary, peripheral, or cerebrovascular disease or diabetes 
with end-organ damage. Patients with congestive heart fail-
ure were excluded. Participants who could not tolerate ACE 
inhibitors were studied in a parallel trial with telmisartan vs 
placebo. In ONTARGET, 25,620 patients were randomized 
to receive telmisartan 80 mg/day, ramipril 10 mg/day, or the 
combination of both drugs, and were followed for 56 months. 
The primary outcome was a composite of death from cardio-
vascular causes, myocardial infarction, stroke, or hospitaliza-
tion for heart failure. Telmisartan was equivalent to ramipril 
for the primary outcome (telmisartan 16.7%, ramipril 16.5%, 
RR: 1.01; 95% CI: 0.94–1.09). Telmisartan caused lower rates 
of cough (1.1% vs 4.2%; P , 0.001) and angioedema (0.1% 
vs 0.3%; P = 0.01) and a higher rate of hypotensive symptoms 
(2.6% vs 1.7%; P , 0.001) when compared with ramipril. 
The combination of the two drugs did not improve outcomes 
and was associated with more adverse events including a 
significantly higher rate of discontinuation (29.3% vs 24.5% 
with ramipril and 23.0% with telmisartan; P , 0.001). These 
findings suggest that RAAS blockade with either telmisartan 
or ramipril is optimal for cardiovascular risk reduction, and 
that telmisartan is comparable to ramipril in patients with 
vascular disease or high risk diabetes, with fewer cough and 
angioedema events.
In the TRANSCEND trial, 5926 high-risk patients intol-
erant to ACE inhibitors, but otherwise similar to ONTAR-
GET population, were randomized to receive telmisartan 
80 mg/day or placebo.16 After 56 months, telmisartan did 
not reduce a composite endpoint of cardiovascular death, 
myocardial infarction, stroke, or hospitalization for heart 
failure in patients with cardiovascular disease or diabetes 
with end-organ damage (telmisartan 15.7%, placebo 17%, 
hazard ratio [HR]: 0.92; 95% CI: 0.81–1.05, P = 0.216). 
However, telmisartan reduced the secondary composite 
outcome of cardiovascular death, myocardial infarction, 
and stroke (telmisartan 13%, placebo 14.8%; odds ratio 
[OR]: 0.86; 95% CI: 0.74–1.00; P = 0.045), which was 
the HOPE composite outcome. In contrast with the HOPE 
study, a neutral effect of telmisartan on hospitalizations for 
heart failure was observed, and may be due to a higher use 
of diuretics (32.8%) and ß-blockers (57.2%) in the placebo 
arm of TRANSCEND, in contrast with 15.2% and 39.8%, Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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respectively in the placebo arm of the HOPE trial a decade 
ago. Therefore TRANSCEND validates the role of ARBs in 
reducing cardiovascular risk in high-risk patients and does 
not contradict ONTARGET.
PRoFESS (PReventiOn regimen For Effectively   avoiding 
Second Strokes) is another large randomized controlled 
trial that enrolled 20,322 patients older than 50 years of age 
who had an ischemic stroke in the previous 120 days and 
were clinically and neurologically stable.17 Patients were 
  randomized to receive telmisartan 80 mg/day vs placebo, 
and were followed for 2.5 years. The primary outcome 
was recurrent stroke, and secondary outcomes were major 
cardiovascular events (death from cardiovascular causes, 
recurrent stroke, myocardial infarction, or new or worsening 
heart failure) and new-onset diabetes. Therapy with telmis-
artan initiated soon after an ischemic stroke and continued 
for 2.5 years did not significantly lower the rate of recurrent 
stroke, major cardiovascular events, or diabetes. Post hoc 
analyses showed that from 6 months on, recurrent stroke rate 
was lower in the telmisartan group (5.3% vs 6.0%; HR: 0.88; 
95% CI: 0.78–0.99). This finding suggests a time-dependent 
benefit of telmisartan and that the trial duration may have 
been too short to detect a difference.
In the NAVIGATOR (Nateglinide and Valsartan in 
Impaired Glucose Tolerance Outcomes Research) trial, val-
sartan, as compared with placebo, did not significantly reduce 
the incidence of cardiovascular outcomes among patients 
with impaired glucose tolerance and cardiovascular disease 
or risk factors (8.1% vs 8.1%; HR: 0.99; 95% CI: 0.86–1.14; 
P = 0.85).18
Telmisartan and effects on left  
ventricular mass
ACE inhibitors are known to reduce LVH. The effects of 
telmisartan and ramipril on LVH were studied in a   subsequent 
analysis of the ONTARGET and TRANSCEND trials.19 In 
TRANSCEND, the prevalence of LVH at entry was 12.7%. 
After 5 years of therapy, it was reduced to 9.9% in the telm-
isartan group, when compared to 12.8% in the placebo group 
(OR: 0.79; 95% CI: 0.68–0.91; P = 0.0017). Furthermore, 
telmisartan reduced new-onset LVH by 37% when compared 
with placebo. However in patients with LVH at entry, regres-
sion of LVH was similar in both groups. In ONTARGET, 
telmisartan showed a trend to be slightly, but not significantly, 
more effective than ramipril in reducing LVH (OR: 0.92; 95% 
CI: 0.83–1.01; P = 0.07). The combination of the telmisartan 
and ramipril did not provide any additional benefit com-
pared to ramipril (OR: 0.93; 95% CI: 0.84–1.02; P = 0.12). 
  New-onset LVH was associated with a higher risk of primary 
outcome during follow-up (HR: 1.77; 95% CI: 1.50–2.07). 
Greater LVH regression with an ARB compared with an 
ACE inhibitor was observed, and might be explained by the 
overactivation of angiotensin II type 2 receptor after   blocking 
the effects of angiotensin II at the angiotensin II type 1 recep-
tor by ARBs.
Telmisartan and atrial fibrillation
Evidence is emerging for a role of RAAS in the pathophysiol-
ogy of atrial fibrillation and a possible role for ACE inhibitors 
and ARBs in primary and secondary prevention of atrial 
fibrillation. A meta-analysis of 23 randomized controlled 
trials involving 87,048 patients showed that RAAS inhibition 
reduced the OR for atrial fibrillation by 33% (P , 0.00001). 
In primary prevention, RAAS inhibition was effective in 
patients with heart failure, hypertension, and LVH but not in 
post-myocardial infarction patients. In secondary prevention, 
the addition of RAAS inhibition to antiarrhythmic drugs 
and medical therapy was also effective.20 In the secondary 
outcomes of the ONTARGET trial, new-onset atrial fibril-
lation was similar in the telmisartan group (6.9%) and the 
ramipril group (6.5%) (RR: 0.97; 95% CI: 0.86–1.09), as well 
as with the combination of both drugs.15 These data suggest 
a certain role for RAAS inhibition in the prevention of atrial 
fibrillation, but further large trials are needed to address this 
specific role.
Telmisartan and prevention  
of diabetes mellitus
RAAS blockade may play a role in the prevention of   diabetes. 
In a post hoc analysis of the HOPE trial, ramipril was associ-
ated with a 34% reduction in the risk of new-onset diabetes 
(RR: 0.66; 95% CI: 0.51–0.85; P , 0.001) when compared 
with placebo.21 However in the DREAM (Diabetes REduc-
tion Assessment with ramipril and rosiglitazone Medica-
tion) trial, ramipril did not reduce the primary outcome of 
diabetes or death in patients with impaired fasting glucose 
or impaired glucose tolerance at low risk for cardiovascu-
lar events, however follow-up was for 3 years only.22 On 
the other hand, in a meta-analysis of 13 studies involving 
approximately 67,000 patients, ACE inhibitors and ARBs 
reduced significantly new-onset diabetes mellitus in patients 
with hypertension or other cardiovascular risk factors with 
a RR of 0.79 (95% CI: 0.74–0.85) for ACE inhibitors and 
0.78 (95% CI: 0.73–0.84) for ARBs.23
In the ONTARGET trial, incidence of new-onset dia-
betes was similar in the telmisartan and ramipril groups.15 Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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In   PRoFESS trial, telmisartan did not prevent new-onset 
diabetes in patients with ischemic stroke.17 In contrast, in 
the TRANSCEND trial, telmisartan reduced significantly 
the   secondary outcome of new-onset diabetes compared to 
placebo (HR: 0.85; 95% CI: 0.71–1.02; P = 0.081).16 Most 
recently in the NAVIGATOR trial, valsartan reduced by 14% 
the incidence of diabetes among patients with impaired glu-
cose tolerance and cardiovascular disease or risk factors.18
Finally, accumulating evidence suggests that telmisartan 
is a partial agonist of the peroxisome proliferator activated 
receptor-gamma (PPAR-γ).24 Multiple in vitro and animal 
studies showed that the activation of this pathway is impor-
tant in dyslipidemia, metabolic syndrome, and vascular 
disease.25–27 Although clinical data is limited, the pleiotropic 
effect of telmisartan as a selective PPAR-γ modulator may 
play an important role in the prevention and treatment of 
diabetes and cardiovascular disease.28,29
Conclusion
Telmisartan is an ARB approved by the FDA for the treat-
ment of hypertension since November 1998. In October 2009, 
based on the results from the ONTARGET trial, telmisartan 
was the first ARB to be granted FDA approval for reduction 
of cardiovascular risk in high-risk patients unable to take 
ACE inhibitors. Within the RAAS inhibition agents, telmis-
artan is characterized by a long duration of effect providing 
24-hour BP control. Although providing similar renoprotec-
tive effects, telmisartan was associated with a better reduction 
of protein excretion than valsartan. In addition, evidence is 
emerging for a potential role of telmisartan and other ARBs 
in the prevention of new-onset diabetes and the prevention 
of atrial fibrillation. Finally, based on the ONTARGET and 
TRANSCEND studies, RAAS blockade with telmisartan 
is shown to provide optimal cardioprotection in high-risk 
patients, along with a good tolerance profile.
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